利伐沙班的售价是多少？

Rivaroxaban was approved for marketing in Canada and the European Union on September 15 and October 1, 2008 respectively. Rivaroxaban tablets were approved for marketing by the State Food and Drug Administration in March 2009. Approved by the FDA on July 1, 2011, the drug is used to prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery. Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Rivaroxaban does not inhibit thrombin and has no proven effect on platelets. A dose-dependent inhibition of factor xa activity by rivaroxaban has been observed in humans. Today let’s find out how much does rivaroxaban cost?

Price: 1. The selling price of Rivaroxaban in the United States: Specification: 10mg-10 tablets/box, pharmacy price: US$156.24; Specification: 15mg-30 tablets/box, pharmacy price: US$438.67; Specification: 20mg-30 tablets/box, pharmacy price: US$553.65. 2. The price of rivaroxaban in China: Domestic rivaroxaban is the original drug produced by Bayer Pharma AG/Germany Bayer Pharmaceuticals. Specification: 10mg-5 tablets/box, priced at about 138$; Specification: 15mg-7 tablets/box, priced at about 199$; Specification: 20mg-7 tablets/box, priced at about 263$. 3. The specifications of rivaroxaban available abroad are 15mg*28 tablets; the price of 20mg*28 tablets is around $600. Please consult Medical Companion Travel for price details.

Rivaroxaban dose-dependently inhibits the activity of factor In clinical practice, rivaroxaban tablets are mainly used to prevent thrombosis or after surgery.

The indications of rivaroxaban are: 1. Used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. 

The above is the indications of rivaroxaban, I hope it can help you!